Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bipolar disorder
Biotech
J&J jettisons several programs, including ph. 2 Alzheimer's work
Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field.
Gabrielle Masson
Oct 15, 2024 2:00pm
Bipolar research initiative announces $36M in new funding
Sep 30, 2024 1:13pm
Rapport talks up $122M IPO for proof-of-concept epilepsy trials
Jun 3, 2024 7:10am
Alvogen snags NRx's bipolar depression drug in $330M deal
Jun 7, 2023 6:30am
AbbVie doubles down on Gedeon Richter pact
Mar 11, 2022 9:35am
Alkermes sees swift turnaround for rejected schizophrenia med
Dec 29, 2020 8:18am
